www.nascentbiotech.com
Open in
urlscan Pro
209.182.193.252
Public Scan
Submitted URL: http://www.nascentbiotech.com/
Effective URL: https://www.nascentbiotech.com/
Submission: On October 21 via api from US — Scanned from DE
Effective URL: https://www.nascentbiotech.com/
Submission: On October 21 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
* Products * Pritumumab * CLNH5 * MultiPharm * Investors * Corporate Governance * Contact Investor Relations * News * About * Corporate Management * Board of Directors * Science Advisory Board * Contact * Products * Pritumumab * CLNH5 * MultiPharm * Investors * Corporate Governance * Contact Investor Relations * News * About * Corporate Management * Board of Directors * Science Advisory Board * Contact PRITUMUMAB IS A PROPRIETARY MONOCLONAL ANTIBODY (MAB) TARGETING A NOVEL ANTIGEN ON CANCER CELLS. PRITUMUMAB HAS RECEIVED FDA ORPHAN DRUG STATUS LATEST NEWS FROM NASCENT BIOTECH NASCENT BEGINS ENROLLMENT OF FINAL PATIENT COHORT TO COMPLETE PHASE ONE CLINICAL RESEARCH October 4, 2022 Corporate News, Press Releases, Science News VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...] 0 NASCENT BIOTECH COMPLETES FOURTH COHORT IN PHASE 1 HUMAN TRIAL FOR PRIMARY AND METASTATIC BRAIN CANCER September 13, 2022 Corporate News, Press Releases, Science News NASCENT BIOTECH RECEIVES NOTICE OF ALLOWANCE FROM USPTO FOR ISSUANCE OF ADDITIONAL PATENT July 19, 2022 Science News Load More DELIVERING HUMAN ANTIBODIES FOR THE TREATMENT OF CANCER © NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.